Pfizer (PFE) Tax Provisions (2009 - 2026)

Pfizer has disclosed Tax Provisions across 18 years of filings, most recently posting $461.0 million for Q1 2026.

• In Q1 2026, Tax Provisions rose 343.92% year-over-year to $461.0 million; the TTM figure through Mar 2026 stood at $384.0 million (up 88.24% YoY), while the FY2025 annual figure was -$266.0 million, down 850.0% from the prior year.
• Tax Provisions improved to $461.0 million in Q1 2026, from -$2.0 million in the prior quarter.
• Over the last five years, Tax Provisions for PFE reached as high as $1.6 billion in Q3 2022 and fell as low as -$964.0 million in Q4 2023.
• The 5-year median for Tax Provisions is $141.0 million (2025), against an average of $172.4 million.
• Annual changes were most pronounced in 2023 — Tax Provisions plunged 370.79% — and 2026, when it jumped 343.92%.
• A 5-year view of Tax Provisions shows it stood at $356.0 million in 2022, then plunged by 319.1% to -$780.0 million in 2023, then soared by 130.0% to $234.0 million in 2024, then sank by 100.85% to -$2.0 million in 2025, then soared by 23150.0% to $461.0 million in 2026.
• According to Business Quant data, Tax Provisions over the past three periods registered $461.0 million, -$2.0 million, and -$216.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.